Drug Profile
Mecobalamin - Eisai
Alternative Names: E 0302Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class Antianaemics; Vitamins
- Mechanism of Action Methyltransferase stimulants; Vitamin B 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Amyotrophic lateral sclerosis
- No development reported Vitamin B deficiency
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Vitamin-B-deficiency(In volunteers) in New Zealand (PO, Tablet)
- 27 May 2022 Mecobalamin - Eisai receives Orphan Drug status for Amyotrophic lateral sclerosis in Japan
- 26 May 2022 Eisai plans to re-submit NDA to the Japanese Ministry of Health, Labour and Welfare for Amyotrophic lateral sclerosis in 2023